Brief: Sk Bioscience Submits Ind For Phase 1/2 Clinical Trial Of Adjuvanted Influenza Vaccine Candidate
17/07/2025 12:58
SK Bioscience Co Ltd 302440.KS: SK BIOSCIENCE SUBMITS IND FOR PHASE 1/2 CLINICAL TRIAL OF ADJUVANTED INFLUENZA VACCINE CANDIDATE SK BIOSCIENCE CO LTD - INTERIM RESULTS FROM PHASE 1/2 TRIAL EXPECTED BY 2027 Source text: ID:nPn3XHzPPa Further company coverage: 302440.KS
Recent news on SK Bioscience Co
See all newsBrief: SK Bioscience Joins Forces With Global Institutions To Advance Rotavirus Vaccine Development
Brief: SK Bioscience Files For First-In-Human Trial Of Universal Coronavirus Vaccine GBP511 Phase 1/2 Study In Australia
Novavax beats quarterly revenue estimates on milestone payment (updated)
Brief: Sk Bioscience Submits Ind For Phase 1/2 Clinical Trial Of Adjuvanted Influenza Vaccine Candidate
Brief: SK Bioscience - Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine